Anavex Life Sciences Corp.
NASDAQ:AVXL
5.31 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 | 0 | 0 | 0.012 | 0 | 0.063 | 0.013 | 0 | 0.075 | 0.07 | 0.001 | 0.003 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.001 | 0 | 0 | -0.012 | 0 | -0.063 | -0.013 | 0 | -0.075 | -0.07 | -0.001 | -0.003 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 43.717 | 37.916 | 32.984 | 25.232 | 22.26 | 13.344 | 10.672 | 7.254 | 2.272 | 0.732 | 0.264 | 2.654 | 2.597 | 2.729 | 2.14 | 1.479 | 0.96 | 0 | 0 | 0 |
| General & Administrative Expenses
| 12.039 | 13.07 | 9.018 | 5.857 | 6.847 | 5.989 | 5.008 | 8.335 | 4.837 | 2.237 | 1.869 | 1.552 | 3.439 | 2.912 | 2.594 | 3.79 | 0.618 | 0.025 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.108 | 0.134 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.039 | 13.07 | 9.018 | 5.857 | 6.847 | 5.989 | 5.008 | 8.335 | 4.837 | 2.237 | 1.869 | 1.66 | 3.573 | 2.912 | 2.594 | 3.79 | 0.618 | 0.025 | 0.092 | 0 |
| Other Expenses
| 2.718 | 3.323 | -0.054 | -0.15 | -0.299 | 1.63 | 2.023 | 0.151 | 0 | 0.2 | -0.977 | 0.002 | 0.01 | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 55.756 | 50.986 | 41.947 | 30.938 | 28.808 | 19.185 | 15.539 | 14.877 | 7.109 | 2.969 | 2.133 | 4.316 | 6.181 | 5.641 | 4.734 | 5.27 | 1.578 | 0.026 | 0.092 | 0.014 |
| Operating Income
| -47.498 | -54.396 | -41.921 | -30.758 | -28.752 | -19.185 | -15.539 | -14.877 | -7.109 | -2.969 | -2.133 | -4.321 | -6.181 | -5.648 | -4.734 | -5.27 | -1.578 | -0.026 | -0.092 | -0.014 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.678 | 6.776 | 4.28 | 4.501 | 2.539 | 1.58 | 2.051 | 0.164 | 0.071 | 0.233 | -1.511 | -3.842 | -1.036 | -2.85 | -0.708 | -0.01 | 0.001 | 0 | 0 | 0 |
| Income Before Tax
| -47.498 | -47.619 | -37.641 | -26.258 | -26.213 | -17.381 | -13.401 | -14.707 | -12.108 | -11.368 | -3.7 | -8.163 | -7.217 | -8.498 | -5.442 | -5.28 | -1.577 | -0.026 | -0.091 | 0 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.007 | 0.358 | 0.268 | 0.023 | 0.082 | 0.073 | 0.06 | 0.03 | 0.072 | 0.007 | 0.051 | 3.986 | 1.127 | 3.142 | 0.765 | 0.082 | 0.003 | 0 | 0 | 0.014 |
| Net Income
| -47.491 | -47.978 | -37.909 | -26.28 | -26.295 | -17.453 | -13.46 | -14.737 | -12.108 | -11.368 | -3.7 | -8.302 | -7.307 | -8.783 | -5.499 | -5.351 | -1.58 | -0.026 | -0.092 | -0.014 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.6 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.005 | -0.021 | -0.008 |
| EPS Diluted
| -0.6 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.005 | -0.021 | -0.008 |
| EBITDA
| -47.498 | -50.082 | -41.68 | -31.064 | -28.881 | -19.135 | -15.567 | -15.04 | -12.106 | -11.593 | -2.137 | -0.472 | -5.143 | -2.791 | -4.026 | -5.26 | -1.579 | -0.026 | -0.092 | -0.014 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |